WNT10A and hepatocellular carcinoma: Treatment of human HCC cells with Trametinib upregulated Wnt10a expression, and additional inhibition of PORCN suppressed CD133 induction (Figure 3—figure supplement 2L), suggesting a role of Wnt10a in CD133 induction under proliferative signal deficiency.